Please login to the form below
tenofovir disoproxil
This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
However, total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020, due to the loss of exclusivity of its HIV drugs Truvada, tenofovir disoproxil fumarate and
Latest news
-
Gilead set to acquire hepatitis specialist MYR for €1.15bn
In the phase 2 MYR202 study, 54 of 90 patients treated with Hepcludex and tenofovir disoproxil fumarate (TDF) had at least a 2 log10 HDV RNA decline or undetectable HDV RNA
-
NHS England will make PrEP for HIV available in April
The PrEP Impact Trial is using Mylan's generic version of Gilead Sciences’ antiretroviral therapy Truvada (emtricitabine/tenofovir disoproxil) but is due to come to an end in October.
-
Gilead builds case for Descovy PrEP after FDA approval
Descovy (emtricitabine/tenofovir alafenamide) claimed its FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green
-
Gilead claims FDA okay for Descovy as second PrEP option
Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing
-
MSD claims EU approval for two HIV products
The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,
Gilead set to acquire hepatitis specialist MYR for €1.15bn
NHS England will make PrEP for HIV available in April
Gilead builds case for Descovy PrEP after FDA approval
MSD claims EU approval for two HIV products
More from news
Approximately 5 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
Choices, choices: the rapidly evolving HIV treatment landscape
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
- Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
- OPEN Health Acquires ARK
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Lucid Group celebrates a double win at Communiqué 2021
- Live Webinar: Driving Healthcare Decisions with Natural Language Processing
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
